Signatories of the Cambridge Declaration By Cat Oettinger | 19 Jun, 2008

Add your name by replying to this discussion.

Attached resource:
  • THE CAMBRIDGE DECLARATION: Towards Clinical Trials for Drug-Resistant Tuberculosis Cambridge, Massachusetts, USA June 12, 2008 (download, 159.7 KB)

    Summary: THE CAMBRIDGE DECLARATION:
    Towards Clinical Trials for Drug-Resistant Tuberculosis
    Cambridge, Massachusetts, USA
    June 12, 2008

    Because

    • today millions of people are living with drug-resistant tuberculosis (TB),
    • drug-resistant TB, which is transmissible and deadly, represents a public-health emergency,
    • universal access to effective TB treatment is unachievable with current tools,
    • inadequate treatment of drug-resistant TB leads to the emergence of extensively drug-resistant (XDR) TB, and
    • there are huge gaps in our understanding of how to best treat drug-resistant TB,

    we express extreme concern that the best available treatments are of limited efficacy and are reaching only a small fraction of people who need them. The others are left to die, with no or inadequate treatment.

    On June 10-12, 2008, stakeholders from communities, NGOs, governments, donors, industry, and academia met in Cambridge, Massachusetts, USA, and declared the formation of a movement that will:

    • conduct priority clinical trials that test strategies in adults and children:
    > to shorten and improve treatment for drug-resistant TB, and
    > to prevent drug-resistant TB
    • mobilize the resources needed for these trials
    • build the capacity of trial sites
    • report to stakeholders on progress made, and
    • ensure that these efforts complement those of other groups, and address the critical unmet needs outlined above.

    For more information, or to join protocol-writing groups, please contact:
    drtbworkshop @gmail.com

    SIGNATORIES, 2 July 2008

    1. Ms. Paula Akugizibwe, AIDS and Rights Alliance for Southern Africa, Namibia
    2. Dr. Elijah Amooti, African Eye Trust, England
    3. Mr. Sidney Atwood, Brigham and Women’s Hospital, USA
    4. Dr. Renuka Babu, Medicine in Need, USA
    5. Dr. Jaime Bayona, Socios En Salud-Sucursal Peru, Peru
    6. Dr. Mercedes Becerra, Harvard Medical School, USA
    7. Dr. Nulda Beyers, Desmond Tutu TB Centre, South Africa
    8. Dr. Cesar Bonilla, National Health Strategy for TB Prevention and Control, Peru
    9. Dr. Maryline Bonnet, Epicentre / Médecins Sans Frontières, Switzerland
    10. Dr. William Burman, Denver Public Health, USA
    11. Dr. Jose A. Caminero, International Union against Tuberculosis and Lung Disease, France
    12. Dr. Peter Cegielski, U.S. Centers for Disease Control and Prevention, USA
    13. Dr. Richard Chaisson, Johns Hopkins University School of Medicine, USA
    14. Dr. Frank Cobelens, KNCV Tuberculosis Foundation, The Netherlands
    15. Dr. Theodore Cohen, Brigham and Women’s Hospital, USA
    16. Dr. Margareth Dalcolmo, Helio Fraga Reference Center - FIOCRUZ / MoH, Brazil
    17. Dr. Charles Daley, National Jewish Medical and Research Center, USA
    18. Dr. Manfred Danilovits, Tartu University Lung Clinic, National Tuberculosis Program, Estonia
    19. Mr. Karel De Beule, Tibotec, Belgium
    20. Dr. Victor De Gruttola, Harvard School of Public Health, USA
    21. Dr. Mary Ann DeGroote, Colorado State University, USA
    22. Dr. Tine De Marez, Tibotec, Inc., USA
    23. Dr. Ashwin Dharmadhikari, Brigham & Women’s Hospital, USA
    24. Ms. Nancy Dianis, Westat, USA
    25. Dr. Anne Donnelly, Project Inform, USA
    26. Dr. Kelly Dooley, Johns Hopkins University School of Medicine, USA
    27. Dr. Kathleen Eisenach, University of Arkansas for Medical Sciences, USA
    28. Dr. Gerald Friedland, Yale University School of Medicine, USA
    29. Dr. Robert Gerety, Medicine in Need, USA
    30. Dr. Ann Ginsberg, Global Alliance for TB Drug Development, USA
    31. Dr. Howard Grossman, Fenway Community Health, USA
    32. Dr. Abdul Hamid Salim, Damien Foundation, Bangladesh
    33. Mr. Mark Harrington, Treatment Action Group, USA
    34. Dr. Martin Hirsch, Harvard Medical School, USA
    35. Dr. Timothy Holtz, U.S. Centers for Disease Control and Prevention, USA
    36. Dr. Robert Horsburgh, Boston University School of Public Health, USA
    37. Dr. Gary Horwith, Sequella, Inc., USA
    38. Dr. Frauke Jochims, Médecins Sans Frontières, Switzerland
    39. Dr. Salmaan Keshavjee, Harvard Medical School, USA
    40. Dr. Michael Kimerling, University of Alabama at Birmingham School of Medicine, USA
    41. Dr. Serena Koenig, Brigham and Women’s Hospital, USA
    42. Dr. Kitty Lambregts, KNCV Tuberculosis Foundation, The Netherlands, and MDR-TB Working Group of the Stop TB Partnership, Switzerland
    43. Dr. Vaira Leimane, State Centre of Tuberculosis and Lung Diseases, Latvia
    44. Dr. Christian Lienhardt, International Union Against Tuberculosis and Lung Disease, France
    45. Dr. Pushpa Malla, National Tuberculosis Centre, National Tuberculosis Program, Nepal
    46. Dr. William Mac Kenzie, U.S. Centers for Disease Control and Prevention, USA
    47. Dr. Helen McIlleron, University of Cape Town, South Africa
    48. Dr. Charles Mgone, European and Developing Countries Clinical Trials Partnership, Netherlands
    49. Dr. Fuad Mirzayev, World Health Organization, Switzerland
    50. Prof. Denis Mitchison, St. George’s Hospital, UK
    51. Dr. Carole Mitnick, Harvard Medical School, USA
    52. Dr. Edward Nardell, Brigham and Women’s Hospital, USA
    53. Dr. Eric Nuermberger, Johns Hopkins University School of Medicine, USA
    54. Mrs. Carol Nyirenda, Treatment Advocacy and Literacy Campaign, Zambia
    55. Dr. Thomas Nyirenda, European and Developing Countries Clinical Trials Partnership, South Africa
    56. Ms. Lesley Odendal, Treatment Action Campaign, South Africa
    57. Dr. Charles Peloquin, National Jewish Medical and Research Center, USA
    58. Dr. Sergey Popov, Moscow Medical Academy, Russia
    59. Dr. Alexander Pym, Medical Research Council of South Africa, South Africa.
    60. Dr. Lee Reichman, University of Medicine and Dentistry of New Jersey, USA
    61. Dr. Hind Satti, Partners In Health, Lesotho
    62. Dr. Rajeswari Ramachandran, Tuberculosis Research Centre, India
    63. Dr. Francisco Rosas, Vivir. Participación, Incidencia, y Transparencia, A.C., Mexico
    64. Dr. Leonard Sacks, U.S. Food and Drug Administration, USA
    65. Dr. Jussi Saukkonen, Boston University School of Medicine, USA
    66. Dr. Neil Schluger, Columbia University Medical Center, USA
    67. Dr. Kwonjune Seung, Brigham and Women’s Hospital, USA
    68. Dr. Alexander Sloutsky, Massachusetts State Laboratory Institute, USA
    69. Dr. Thelma Tupasi, Tropical Disease Foundation, Philippines
    70. Dr. Frank van Leth, KNCV Tuberculosis Foundation, The Netherlands
    71. Mr. Wim Vandevelde, European AIDS Treatment Group, Belgium
    72. Dr. Francis Varaine, Médecins Sans Frontières, France
    73. Dr. Andrew Vernon, U.S. Centers for Disease Control and Prevention, USA
    74. Dr. Tido von Schoen-Angerer, Médecins Sans Frontières, Switzerland
    75. Dr. Diana Weil, World Health Organization, Switzerland
    76. Dr. Charles Wells, Otsuka America Pharmaceutical, Inc., USA
    77. Dr. Matteo Zignol, World Health Organization, Switzerland

    The workshop was convened by partners of the MDR-TB Working Group of the Stop-TB Partnership. It was sponsored and organized by: Boston University School of Public Health, International Union Against TB & Lung Disease, KNCV Tuberculosis Foundation, MDR-TB Working Group of the Stop-TB Partnership, Médecins Sans Frontières, Partners In Health/Harvard Medical School, Potts Memorial Foundation, Treatment Action Group, World Health Organization.

    Source: Participants of the DR TB Clinical Trials Workshop

    Publication Date: July 4, 2008

    Language: English

    Keywords: RESIST-TB, Workshop Materials

Replies

 

Cat Oettinger Replied at 5:22 PM, 1 Jul 2008

SIGNATORIES, as of 23 June 2008


1. Ms. Paula Akugizibwe, AIDS and Rights Alliance for Southern Africa, Namibia
2. Mr. Sidney Atwood, Brigham and Women’s Hospital, USA
3. Dr. Jaime Bayona, Socios En Salud-Sucursal Peru, Peru
4. Dr. Mercedes Becerra, Harvard Medical School, USA
5. Dr. Cesar Bonilla, National Health Strategy for TB Prevention and Control, Peru
6. Dr. Maryline Bonnet, Epicentre / Médecins Sans Frontières, Switzerland
7. Dr. William Burman, Denver Public Health, USA
8. Dr. Peter Cegielski, U.S. Centers for Disease Control and Prevention, USA
9. Dr. Richard Chaisson, Johns Hopkins University School of Medicine, USA
10. Dr. Frank Cobelens, KNCV Tuberculosis Foundation, The Netherlands
11. Dr. Theodore Cohen, Brigham and Women’s Hospital, USA
12. Dr. Margareth Dalcolmo, Centro de Referência Prof. Hélio Fraga, Brazil
13. Dr. Charles Daley, National Jewish Medical and Research Center, USA
14. Dr. Manfred Danilovits, Tartu University Lung Clinic, National Tuberculosis Program, Estonia
15. Mr. Karel De Beule, Tibotec, Belgium
16. Dr. Victor De Gruttola, Harvard School of Public Health, USA
17. Dr. Mary Ann DeGroote, Colorado State University, USA
18. Dr. Ashwin Dharmadhikari, Brigham & Women’s Hospital, USA
19. Ms. Nancy Dianis, Westat, USA
20. Dr. Kelly Dooley, Johns Hopkins University School of Medicine, USA
21. Dr. Kathleen Eisenach, University of Arkansas for Medical Sciences, USA
22. Dr. Gerald Friedland, Yale University School of Medicine, USA
23. Dr. Robert Gerety, Medicine in Need, USA
24. Dr. Abdul Hamid Salim, Damien Foundation, Bangladesh
25. Mr. Mark Harrington, Treatment Action Group, USA
26. Dr. Martin Hirsch, Harvard Medical School, USA
27. Dr. Timothy Holtz, U.S. Centers for Disease Control and Prevention, USA
28. Dr. Robert Horsburgh, Boston University School of Public Health, USA
29. Dr. Gary Horwith, Sequella, Inc., USA
30. Dr. Frauke Jochims, Médecins Sans Frontières, Switzerland
31. Dr. Salmaan Keshavjee, Harvard Medical School, USA
32. Dr. Michael Kimerling, University of Alabama at Birmingham School of Medicine, USA
33. Dr. Kitty Lambregts, KNCV Tuberculosis Foundation, The Netherlands, and MDR-TB Working Group of the Stop TB Partnership, Switzerland
34. Dr. Vaira Leimane, State Centre of Tuberculosis and Lung Diseases, Latvia
35. Dr. Christian Lienhardt, International Union Against Tuberculosis and Lung Disease, France
36. Dr. Pushpa Malla, National Tuberculosis Centre, National Tuberculosis Program, Nepal
37. Dr. William Mac Kenzie, U.S. Centers for Disease Control and Prevention, USA
38. Dr. Charles Mgone, European and Developing Countries Clinical Trials Partnership, Netherlands
39. Dr. Fuad Mirzayev, World Health Organization, Switzerland
40. Prof. Denis Mitchison, St. George’s Hospital, UK
41. Dr. Carole Mitnick, Harvard Medical School, USA
42. Dr. Edward Nardell, Brigham and Women’s Hospital, USA
43. Dr. Eric Nuermberger, Johns Hopkins University School of Medicine, USA
44. Mrs. Carol Nyirenda, Treatment Advocacy and Literacy Campaign, Zambia
45. Dr. Thomas Nyirenda, European and Developing Countries Clinical Trials Partnership, South Africa
46. Ms. Lesley Odendal, Treatment Action Campaign, South Africa
47. Dr. Charles Peloquin, National Jewish Medical and Research Center, USA
48. Dr. Sergey Popov, Russia Moscow Medical Academy, Russia
49. Dr. Alexander Pym, Medical Research Council of South Africa, South Africa.
50. Dr. Lee Reichman, University of Medicine and Dentistry of New Jersey, USA
51. Dr. Hind Satti, Partners In Health, Lesotho
52. Dr. Rajeswari Ramachandran, Tuberculosis Research Centre, India
53. Dr. Jussi Saukkonen, Boston University School of Medicine, USA
54. Dr. Neil Schluger, Columbia University Medical Center, USA
55. Dr. Kwonjune Seung, Brigham and Women’s Hospital, USA
56. Dr. Alexander Sloutsky, Massachusetts State Laboratory Institute, USA
57. Dr. Thelma Tupasi, Tropical Disease Foundation, Philippines
58. Dr. Frank van Leth, KNCV Tuberculosis Foundation, The Netherlands
59. Mr. Wim Vandevelde, European AIDS Treatment Group, Belgium
60. Dr. Francis Varaine, Médecins Sans Frontières, France
61. Dr. Andrew Vernon, U.S. Centers for Disease Control and Prevention, USA
62. Dr. Tido von Schoen-Angerer, Médecins Sans Frontières, Switzerland
63. Dr. Charles Wells, Otsuka America Pharmaceutical, Inc., USA
64. Dr. Matteo Zignol, World Health Organization, Switzerland

Cat Oettinger Replied at 10:38 AM, 21 Jul 2008

65. Dr. Elijah Amooti, African Eye Trust, England
66. Dr. Renuka Babu, Medicine in Need, USA
67. Dr. Nulda Beyers, Desmond Tutu TB Centre, South Africa
68. Dr. Jose A. Caminero, International Union against Tuberculosis and Lung Disease, France
69. Dr. Anne Donnelly, Project Inform, USA
70. Dr. Tine De Marez, Tibotec, Inc., USA
71. Dr. Ann Ginsberg, Global Alliance for TB Drug Development, USA
72. Dr. Howard Grossman, Fenway Community Health, USA
73. Dr. Serena Koenig, Brigham and Women’s Hospital, USA
74. Dr. Helen McIlleron, University of Cape Town, South Africa
75. Dr. Francisco Rosas, Vivir. Participación, Incidencia, y Transparencia, A.C., Mexico
76. Dr. Leonard Sacks, U.S. Food and Drug Administration, USA
77. Dr. Diana Weil, World Health Organization, Switzerland
78. Dr. Mette Klouman, The Norwegian Heart and Lung Patient Organisation, Norway

Sophie Beauvais Replied at 11:13 AM, 22 Sep 2008

Dear GHDonline members and visitors,

If you wish to sign the Cambridge Declaration, please add your name to this list by clicking on "reply." In addition, if you'd like to join protocol-writing groups and become a member of RESIST-TB, the private community of practice available on GHDonline for stakeholders collaborating to improve and expand DR TB clinical trials, please contact: .

If you are not a member of GHDonline but would like to sign the Cambridge Declaration, please click on "Join" and add "DR TB" in your subject line. As soon as you receive a confirmation of membership, you will be able to proceed as detailed above.

The DR TB Clinical Trials Working Group, or RESIST-TB, was created in June 2008 by stakeholders from communities, NGOs, governments, donors, industry, and academia to:

- conduct priority clinical trials that test strategies in adults and children:
> to shorten and improve treatment for drug-resistant TB, and
> to prevent drug-resistant TB

- mobilize the resources needed for these trials

- build the capacity of trial sites

- report to stakeholders on progress made, and

- ensure that these efforts complement those of other groups, and address the critical unmet needs outlined above.

Vera Belitsky Replied at 11:46 AM, 5 Nov 2008

Prof. Simon Schaaf, University of Stellenbosch, South Africa

David Moore Replied at 8:00 AM, 6 Nov 2008

Dr. David Moore, Imperial College London, UK

Maxine Caws Replied at 1:13 AM, 7 Nov 2008

Maxine Caws

Maxine Caws Replied at 1:16 AM, 7 Nov 2008

Maxine Caws, Oxford University Clinical Research Unit, Vietnam

Susan van den Hof Replied at 4:17 AM, 10 Nov 2008

Susan van den Hof, KNCV Tuberculosis Foundation, The Netherlands

Vera Belitsky Replied at 2:08 PM, 10 Nov 2008

Kelly Stinson, Otsuka America Pharmaceutical, Inc., USA

Vera Belitsky Replied at 5:46 PM, 3 Feb 2009

Dr. O. A. Ekwaro, Integrated TB/HIV Services, UMSOM/IHV-AIDS Relief, Uganda

jayanth devasundaram Replied at 1:22 AM, 4 Feb 2009

Dr. Jayanth Devasundaram
Pennsylvania

Grigory Volchenkov, MD Replied at 4:32 AM, 4 Feb 2009

Dr. Grigory Volchenkov, Vladimir Oblast TB Dispansery, Vladimir, Russia